Navigation Links
caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project With Roche
Date:6/29/2010

BERLIN and BURLINGTON, Mass., June 29 /PRNewswire/ -- caprotec bioanalytics GmbH announced today that it has successfully completed a research collaboration with F. Hoffmann-La Roche, Basel, Switzerland. Under the collaboration research agreement, caprotec used its proprietary CCMS (Capture Compound Mass Spectrometry) technology to analyze the binding characteristics and interaction of one undisclosed drug candidate with its human target proteins.

To identify selectively interacting proteins of a drug molecule, it is coupled to caprotec's Capture Compound™ scaffold and incubated with human cell lysates, subcellular fractions or whole cells. Interacting proteins are then isolated and identified via Liquid Chromatography-Mass Spectrometry/Mass.  Among the protein targets that demonstrated specific binding of Roche's drug molecule were some which show activity in pathways commensurate with the phenotypic profile of the candidate drug molecule.

"The results of this drug-protein profiling study confirm again the capability of our CCMS technology to directly isolate a functional subset of proteins from a complex biological sample for the identification of previously unknown interactions with small molecules," said Dr. Hubert Koster, CEO of caprotec. "This fills a crucial technological gap in the arsenal of methods available for optimizing drug structures and to select the most promising candidate drugs before entering the clinical trial process as well as drug safety assessment."

"This project demonstrated that the CCMS technology is robust and yields high quality results that are complementary to our internal research efforts. We are very pleased with the outcome of this collaboration", stated Dr. Stephan Rover, Scientific Expert for Discovery Chemistry at Roche.

About caprotec bioanalytics GmbH

caprotec bioanalytics is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. The company focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds (CCs). They enable a targeted isolation of proteins directly from complex biological samples in solution. After isolation, the captured proteins including membrane proteins are identified by mass spectrometry. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of protein biomarkers. The technology is protected by a broad patent portfolio. The company is supported by an international scientific advisory board including one Nobel Laureate.

www.caprotec.com


'/>"/>
SOURCE caprotec bioanalytics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website
2. Serono Symposia International Foundation in Collaboration With ESHRE Announces Public Competition in Reproductive Medicine
3. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
4. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
5. Breckenridge Announces Approval of Anastrozole Tablets
6. American Medical Systems Announces FDA Clearance for MiniArc(R) Precise Single-Incision Sling
7. Recondo Technology Announces Integration Initiative for US Hospital Systems
8. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
9. Solta Medical Announces Thermage CPT™ and Fraxel re:store® Dual Systems Receive Health Canada Approval
10. Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments
11. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 Global Interventional Radiology ... the global interventional radiology market analyzes the current ... comprises an elaborate executive summary, including a market ... and sub-segments. The research is a combination ... the bulk of our research efforts along with ...
(Date:12/8/2016)... Dec. 8, 2016 Allergy Diagnostics Market: ... and tests that are used to determine the ... milk, or drugs etc. in the samples by ... immune system. The report on global allergy diagnostics ... the market. The report consists of an executive ...
(Date:12/8/2016)... NORWALK, Connecticut , 8 de dezembro de 2016  A Mederi ... a terapia Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico ... Reading ... Live Stretta procedure performed ... Director of Endoscopy at Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... Charleston, WV (PRWEB) , ... December 08, 2016 ... ... that it will become Quality Insights beginning January 1, 2017. The name ... emphasizes its commitment to measuring and improving health care quality. , “We are ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
Breaking Medicine News(10 mins):